Massachusetts Institute of Technology has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to cyclin-dependent kinase 9 (CDK9)-targeting ...

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates ...

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates prescribing ...

Regimen for treatment-experienced patients Use treatment history, past and current resistance profiles, and identifiable causes of treatment failure to design new regimen with at least 2 ...

An Uppthera Inc. patent describes new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13 ...

When given with known CYP3A inducers (including but not limited to efavirenz, rifampin, carbamazepine, phenobarbital, and phenytoin), the maraviroc dosage should be increased to 600 mg twice daily.